Summary
Boston Scientific Corporation reported net sales of $1.843 billion for the second quarter of 2015, a slight decrease of 2% compared to the prior year's quarter, largely influenced by unfavorable foreign currency exchange rates. On a constant currency basis, excluding divested businesses, net sales increased by 6%. The company reported a net income of $102 million ($0.08 per diluted share) for the quarter, a significant improvement from a net income of $4 million ($0.00 per diluted share) in the same period last year. This improvement was driven by the resolution of significant litigation expenses that heavily impacted the prior year's quarter. Operationally, the company saw positive sales growth in its MedSurg segment (6% constant currency), primarily from Endoscopy and Neuromodulation. However, the Cardiovascular and Rhythm Management segments experienced declines in net sales, particularly in Cardiac Rhythm Management which saw a 1% decrease on a constant currency basis, impacted by lower defibrillator and pacemaker sales in the U.S. The company also completed a significant acquisition of the American Medical Systems male urology portfolio for $1.6 billion, signaling strategic investment in future growth. Despite a decrease in operating cash flow for the first half of the year, largely due to a $600 million litigation payment, the company maintained adequate liquidity and robust covenant compliance.
Financial Highlights
53 data points| Revenue | $1.84B |
| Cost of Revenue | $540.00M |
| Gross Profit | $1.30B |
| SG&A Expenses | $700.00M |
| Operating Expenses | $1.08B |
| Operating Income | $219.00M |
| Interest Expense | $106.00M |
| Net Income | $102.00M |
| EPS (Basic) | $0.08 |
| EPS (Diluted) | $0.08 |
| Shares Outstanding (Basic) | 1.34B |
| Shares Outstanding (Diluted) | 1.36B |
Key Highlights
- 1Net sales decreased by 2% year-over-year to $1.843 billion, but showed a 6% increase on a constant currency basis (excluding divestitures).
- 2Net income significantly improved to $102 million ($0.08/share) from $4 million ($0.00/share) in the prior year's quarter, aided by lower litigation charges.
- 3MedSurg segment sales grew 6% on a constant currency basis, driven by Endoscopy and Neuromodulation.
- 4Cardiovascular and Rhythm Management segments experienced sales declines on a constant currency basis.
- 5The company completed the $1.6 billion acquisition of the American Medical Systems male urology portfolio.
- 6Operating cash flow for the first half of 2015 was negative ($137 million), primarily due to significant litigation payments.
- 7Gross profit margin improved to 70.7% from 69.9% in the prior year's quarter, driven by cost reductions.